← Back to Home

Huntington’s Disease Gene Therapy AMT-130 Receives FDA Priority Review as Efficacy Evidence Faces Scrutiny

uniQure’s marketing application has entered formal review, with a target decision date of May 1, 2027. Key questions are whether comparisons between early trial data and external controls can support accelerated approval, and how a subsequent randomized trial will confirm benefit.

By SURL BioNews

For people with Huntington’s disease, whether treatment can preserve their gradually declining ability to manage daily life is a more pressing question than the review timeline. On November 2, uniQure announced that the U.S. Food and Drug Administration (FDA) had accepted the biologics license application for its gene therapy ifezuntirgene inilparvovec (AMT-130) and granted priority review, with a target decision date of May 1, 2027. This moves the therapy one step closer to potential market authorization and brings the clinical evidence supporting the application under formal scrutiny.

The company submitted its application through the accelerated approval pathway, but acceptance, priority review, and approval are distinct regulatory milestones. In information published the same day, the International Huntington Association noted that acceptance marks the start of formal review and that AMT-130 remains an investigational therapy. Priority review does not predetermine the outcome, and the target date is not a commitment to market authorization.

At the core of this application are 36-month follow-up data from a Phase 1/2 study. According to uniQure’s announcement filed with the U.S. Securities and Exchange Commission, the analysis used the Enroll-HD natural history database to establish an external control group through propensity score matching, comparing disease progression in treated participants with that of patients with similar baseline characteristics. In other words, the main comparison supporting the application did not come from a concurrent control group randomly assigned within the same trial.

This approach can provide a reference for early research, but it also leaves limitations in interpretation. Matching can reduce differences in known characteristics, yet it cannot guarantee that the two groups are alike in every factor affecting disease progression; care practices, assessment settings, and unrecorded differences could all influence the comparison. More rigorous research is therefore still needed to confirm how much of the observed difference in disease progression can be attributed to the therapy. Acceptance of the application alone cannot establish that conclusion.

The subsequent confirmatory trial will use a different design. The company plans to enroll approximately 200 patients, randomly assigned in a two-to-one ratio to receive gene therapy or standard care, with Total Functional Capacity (TFC) at month 36 as the primary endpoint. This design focuses the assessment on whether patients can maintain function and provides a comparison framework better able to reduce the influence of differences between groups.

However, the confirmatory trial is still being prepared. Information published by the International Huntington Association states that U.S. trial sites are still being confirmed and activated, with patient screening expected to begin by the end of 2026; information about international trial locations is expected to be announced in the first half of 2027. These are current planned timelines and do not mean that patient enrollment has begun.

According to the company’s announcement, the FDA also tentatively plans to convene an advisory committee to discuss the application, but meeting arrangements have not been finalized. The upcoming review will examine whether the existing data are sufficient to support accelerated approval. The answers that matter most to patients—whether the therapy can deliver lasting, verifiable functional benefits and whether its risks are acceptable—must still be established gradually through comprehensive efficacy and safety assessments and subsequent research.

References

  1. uniQure via GlobeNewswire
  2. uniQure via SEC EDGAR
  3. International Huntington Association